User profiles for Andrea M. Collins
 | Andrea CollinsSenior Clinical Academic in Respiratory Medicine, Liverpool School of Tropical Medicine Verified email at lstmed.ac.uk Cited by 12446 |
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, QE Bhorat, S Bibi, C Briner, P Cicconi, AM Collins… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, S Bibi, C Briner, P Cicconi, EA Clutterbuck, AM Collins… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
…, P Cicconi, S Charlton, EA Clutterbuck, AM Collins… - The Lancet, 2021 - thelancet.com
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
…, JC Cameron, S Charlton, EA Clutterbuck, AM Collins… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in …
…, JC Cameron, S Charlton, EA Clutterbuck, AM Collins… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
[HTML][HTML] Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials …
…, N Byard, S Camara, LC Gutierrez, AM Collins… - The Lancet, 2021 - thelancet.com
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
Nirsevimab for prevention of hospitalizations due to RSV in infants
…, K Cathie, F Flamein, M Knuf, AM Collins… - … England Journal of …, 2023 - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …
Controlled Human Infection and Rechallenge with Streptococcus pneumoniae Reveals the Protective Efficacy of Carriage in Healthy Adults
…, EN Miyaji, AD Wright, AM Collins… - American journal of …, 2013 - atsjournals.org
Rationale: The immunological and protective role of pneumococcal carriage in healthy adults
is not known, but high rates of disease and death in the elderly are associated with low …
is not known, but high rates of disease and death in the elderly are associated with low …
[HTML][HTML] Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination
Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus
infection in animal models. In humans, the capacity of peripheral vaccination to generate …
infection in animal models. In humans, the capacity of peripheral vaccination to generate …
[HTML][HTML] Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung
Pneumococcal carriage is both immunising and a pre-requisite for mucosal and systemic
disease. Murine models of pneumococcal colonisation show that IL-17A-secreting CD4 + T-…
disease. Murine models of pneumococcal colonisation show that IL-17A-secreting CD4 + T-…